|Chemical and physical data|
|Molar mass||502.392 g/mol g·mol−1|
|3D model (JSmol)|
MIN-117 (known formerly as WF-516) is an investigational antidepressant which is under development by Minerva Neurosciences for the clinical treatment of major depressive disorder (MDD). It is described as a 5-HT1A and 5-HT2A receptor antagonist and inhibitor of serotonin and dopamine reuptake, and is also reported to possess affinity for the α1A- and α1B-adrenergic receptors. As of May 2015, MIN-117 is in phase II clinical trials for MDD.
|This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.|